• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neutralizing antibodies against KP.2 and KP.3: why the current vaccine needs an update.

作者信息

Gillot Constant, David Clara, Dogné Jean-Michel, Cabo Julien, Douxfils Jonathan, Favresse Julien

机构信息

Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium.

Research and Development Department, Qualiblood s.a., Namur, Belgium.

出版信息

Clin Chem Lab Med. 2024 Aug 16;63(3):e82-e85. doi: 10.1515/cclm-2024-0919. Print 2025 Feb 25.

DOI:10.1515/cclm-2024-0919
PMID:39147380
Abstract
摘要

相似文献

1
Neutralizing antibodies against KP.2 and KP.3: why the current vaccine needs an update.针对KP.2和KP.3的中和抗体：为何当前疫苗需要更新。
Clin Chem Lab Med. 2024 Aug 16;63(3):e82-e85. doi: 10.1515/cclm-2024-0919. Print 2025 Feb 25.
2
Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.奥密克戎变种JN.1、KP.2和KP.3对新冠康复者及疫苗接种者的多克隆和单克隆抗体的免疫逃逸
Antiviral Res. 2025 Mar;235:106092. doi: 10.1016/j.antiviral.2025.106092. Epub 2025 Jan 27.
3
Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.新型冠状病毒XEC变异株N端结构域糖基化突变在免疫逃逸、细胞间融合及刺突蛋白稳定性中的作用
J Virol. 2025 Apr 15;99(4):e0024225. doi: 10.1128/jvi.00242-25. Epub 2025 Mar 26.
4
A Decrease of Antibodies Against SARS-CoV-2 Antigens Does Not Reflect a Decrease of Neutralization Rate: A Prospective Study to Evaluate Kinetic and Dynamic Humoral Immune Response After Vaccination During Pregnancy.抗SARS-CoV-2抗原抗体水平降低并不反映中和率下降：一项评估孕期接种疫苗后体液免疫反应动力学和动态变化的前瞻性研究。
Am J Reprod Immunol. 2025 Feb;93(2):e70053. doi: 10.1111/aji.70053.
5
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.两剂蛋白亚单位疫苗 MVC-COV1901 初免后加强接种多剂 mRNA 疫苗可增强针对新型 SARS-CoV-2 变异株的体液和细胞免疫应答。
Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25.
6
Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.体液和细胞免疫应答对 SARS-CoV-2 载体、混合和匹配或 mRNA 疫苗的反应，以及这两种免疫反应之间的关系。
Microbiol Spectr. 2022 Aug 31;10(4):e0249521. doi: 10.1128/spectrum.02495-21. Epub 2022 Aug 10.
7
Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare workers: An observational study.两种不同 SARS-CoV-2 疫苗在一组医护人员中的体液和细胞免疫反应：一项观察性研究。
J Immunol Methods. 2024 May;528:113665. doi: 10.1016/j.jim.2024.113665. Epub 2024 Mar 14.
8
Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine.接种Comirnaty或Spikevax单价XBB1.5新冠疫苗后老年人的安全性和免疫原性比较。
J Infect. 2025 Jan;90(1):106374. doi: 10.1016/j.jinf.2024.106374. Epub 2024 Dec 8.
9
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.多元化的体液免疫和加强疫苗的影响：初次或第二次加强针前后 SARS-CoV-2 抗体特征和奥密克戎 BA.2 的中和作用。
Microbiol Spectr. 2024 Oct 3;12(10):e0060524. doi: 10.1128/spectrum.00605-24. Epub 2024 Aug 20.
10
Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.接种疫苗和奥密克戎 BA.1/BA.2 感染恢复期增强了针对 BA.4/5 的系统性但非黏膜免疫。
Microbiol Spectr. 2023 Jun 15;11(3):e0516322. doi: 10.1128/spectrum.05163-22. Epub 2023 Apr 26.

引用本文的文献

1
Emerging SARS-CoV-2 variants: genomic shifts, immune evasion, and therapeutic perspectives.新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体：基因组变化、免疫逃逸及治疗前景
Mol Biol Rep. 2025 Sep 10;52(1):886. doi: 10.1007/s11033-025-11009-w.
2
From immune evasion to broad binding: computational optimization of SARS-CoV-2 RBD-targeting nanobody.从免疫逃逸到广泛结合：针对严重急性呼吸综合征冠状病毒2受体结合域的纳米抗体的计算优化
Front Immunol. 2025 Aug 14;16:1637955. doi: 10.3389/fimmu.2025.1637955. eCollection 2025.
3
Single amino acid substitution at position 614 in SARS-CoV-2 Spike Protein alters viral assembly and infectivity.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白第614位的单氨基酸取代会改变病毒组装和传染性。
Virus Res. 2025 Aug 22;360:199624. doi: 10.1016/j.virusres.2025.199624.
4
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages.重组XBB.1.5加强针可诱导对包括KP.2和KP.3在内的JN.1亚谱系产生强大的中和作用。
Signal Transduct Target Ther. 2025 Jan 27;10(1):47. doi: 10.1038/s41392-025-02139-5.
5
Evaluation of neutralizing antibody titers against SARS-CoV-2 JN.1 omicron subvariant during pregnancy - A case series study.孕期针对新型冠状病毒JN.1奥密克戎亚变体的中和抗体滴度评估——一项病例系列研究
Heliyon. 2024 Dec 19;11(1):e41249. doi: 10.1016/j.heliyon.2024.e41249. eCollection 2025 Jan 15.